ReviewFrontiers in immunology2026
Synergistic immunomodulation: integrating physical ablation with immune checkpoint inhibitors for metastatic colorectal carcinoma.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal carcinoma (CRC) is one of the most common malignant tumors worldwide, with treatment options including surgery, chemotherapy, radiotherapy, and targeted therapy. However, the overall efficacy of treatment for metastatic CRC (mCRC) remains unsatisfactory. In recent years, immune checkpoint inhibitors (ICIs) have shown good therapeutic effects in some patients, but the overall response rate remains low. Physical ablation (PA) is a localized treatment modality that, in addition to eradicating targeted lesions, promotes anti-tumor immunity by releasing tumor-associated antigens from damaged tumor cells. ICIs enhance this PA-elicited anti-tumor immune response by inhibiting immunosuppressive pathways and unleashing T-cell activity, resulting in a synergistic anti-tumor effect. This article reviews the latest research on the treatment of mCRC with PA (mainly including radiofrequency ablation, microwave ablation, and cryoablation) combined with ICIs, focusing on how PA combined with ICIs can reshape the tumor immune microenvironment to produce a synergistic anti-tumor immune response. Finally, this article also discusses the challenges currently faced by the combined treatment and looks forward to future research directions, aiming to provide a new treatment strategy to improve the clinical prognosis of mCRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.